The revised
IMI Scientific Research Agenda

Daan JA Crommelin, PhD, vice chair of the Scientific Committee of the Innovative Medicines Initiative
Utrecht University, The Netherlands
27 February 2012
The Scientific Committee is a body of the IMI Joint Undertaking and provides scientific advice to the Governing Board.

The Scientific Committee is currently composed of 14 scientists/experts from different background (academia, SMEs, ‘big pharma’, patient organizations, regulators) that have been appointed further to recommendations made by the States Representatives Group.

The Scientific Committee
• gives strategic, science-based recommendations to the IMI JU
• advises on the continued relevance of the Research Agenda and the scientific priorities, which are the basis for Call Topics
Scientific Committee: its role.... Strategic Research Agenda
The IMI Research Agenda 2008/9

- The IMI Research Agenda is a multiannual plan.
- It identifies principal research bottlenecks in the biopharmaceutical R&D process.
- It describes recommendations to overcome these bottlenecks and a plan to guide their implementation.
- It focuses on four areas: predicting safety, predicting efficacy, knowledge management, education and training.
- It is a tool to communicate the IMI mission.
The Original Matrix of the IMI SRA

Knowledge Management
- Predictive pharmacology
- Predictive toxicology
- Identification of biomarkers
- Patient recruitment
- Validation of biomarkers
- Benefit/Risk assessment with regulatory authorities

Education & Training

Efficacy → Safety

Brain Disorders
Inflammatory Diseases
Metabolic Diseases
Infectious Diseases
The Updated Structure of the Revised SRA

**IMI AREAS OF RESEARCH INTEREST**

**NEW PRIORITIES**

**ESTABLISHED PRIORITIES**

**IMI ACTIVITIES**

- **API Technology (Drug Compound Development)**
- **Advanced Formulations**
- **Stem Cells for Drug Development and Toxicity Screening**
- **Integration of Imaging Techniques into Drug Research**
- **Neuro-psychiatric Disorders / Brain Diseases**
- **Inflammatory Diseases**
- **Metabolic Diseases Including Cardiovascular Diseases**
- **Infectious Diseases**
- **Cancer**

**KNOWLEDGE MANAGEMENT**

- **Science Communication**
- **Science Communication**
- **Tools and Techniques**
- **Development in Regulatory Framework**
- **Strategies in R&D**
- **Knowledge Management**

**PATIENTS**

- **IMI AREAS OF RESEARCH INTEREST**

**NEW PRIORITIES**

- **Increasing Practicability of Biomarkers and Biobanks**
- **Coping with Regulatory and Legal Hurdles**
- **Safety Sciences**
- **Pharmacogenetics and Taxonomy of Human Diseases**
- **Pharmacological Interactions at the Molecular level**
- **Rare Diseases and Stratified Therapies**

**KNOWLEDGE MANAGEMENT**

**KNOWLEDGE MANAGEMENT**
Implementing the Revised SRA: the IMI 4th Call for Proposals

- First “Think Big” topics are launched: **EMIF** (€ 24 million from both EFPIA and the public side) and **hiPS** topic (€ 26 million from both EFPIA and public side)

- In addition, new research areas in **pharmaceutical chemistry**, **oral drug delivery**, **binding kinetics**, **optimising delivery of biological macromolecules** are addressed

- The topics will continue to bring together data, resources and expertise from the public and private sectors to improve pharmaceutical research
Subject of today’s discussions:
this is not about (lead) plumbing
SRA and the Scientific Advisory Board......
an evolving relationship